Literature DB >> 3317747

Characterization of a nontoxic monophosphoryl lipid A.

A G Johnson1, M Tomai, L Solem, L Beck, E Ribi.   

Abstract

Gram-negative bacterial endotoxins constitute some of the strongest immunologic adjuvants known. Precluding their use as adjuvants in humans has been the exquisite toxicity of these compounds in extraordinarily small amounts. With the acquisition of precise knowledge of the structure of the active moiety, detoxifying procedures have been developed. These have resulted in the isolation of a monophosphoryl lipid A with a much reduced toxicity that retains the capacity to act as an adjuvant in young mice as well as in immunodeficient aging mice.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3317747     DOI: 10.1093/clinids/9.supplement_5.s512

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  20 in total

1.  Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.

Authors:  Pernille Nordly; Else Marie Agger; Peter Andersen; Hanne Mørck Nielsen; Camilla Foged
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

Review 2.  Old and new adjuvants for hepatitis B vaccines.

Authors:  Geert Leroux-Roels
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

3.  Altered in vivo activity of liposome-incorporated lipopolysaccharide and lipid A.

Authors:  J Dijkstra; J W Mellors; J L Ryan
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

4.  Heat shock proteins: A dual carrier-adjuvant for an anti-drug vaccine against heroin.

Authors:  Candy S Hwang; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2018-11-20       Impact factor: 3.641

5.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

6.  Dissociation of TRIF bias and adjuvanticity.

Authors:  Katharina Richard; Darren J Perkins; Erin M Harberts; Yang Song; Archana Gopalakrishnan; Kari Ann Shirey; Wendy Lai; Alexandra Vlk; Anup Mahurkar; Shreeram Nallar; Lynn D Hawkins; Robert K Ernst; Stefanie N Vogel
Journal:  Vaccine       Date:  2020-05-07       Impact factor: 3.641

7.  The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection.

Authors:  Christopher D Romero; Tushar K Varma; Jason B Hobbs; Aimee Reyes; Brandon Driver; Edward R Sherwood
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

8.  Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria.

Authors:  Paula M Chilton; Diana M Hadel; Thao T To; Thomas C Mitchell; Richard P Darveau
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

9.  Periplasmic cleavage and modification of the 1-phosphate group of Helicobacter pylori lipid A.

Authors:  An X Tran; Mark J Karbarz; Xiaoyuan Wang; Christian R H Raetz; Sara C McGrath; Robert J Cotter; M Stephen Trent
Journal:  J Biol Chem       Date:  2004-10-15       Impact factor: 5.157

Review 10.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.